All News

Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

Complete response rates were observed consistently across patient subgroups in those with high-risk BCG-unresponsive non-muscle invasive bladder cancer.

A recommendation from an independent data monitoring committee prompted the discontinuation of the phase 3 CAPItello-280 trial.

18F-FDG PET/CT staging of lymph node metastases in patients with bladder cancer undergoing radical cystectomy did not correlate with worse survival outcomes.

Data show that patients who undergo grade group 1 prostatectomies may experience an increased likelihood of higher risk features.

A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

Findings may establish a framework for assisting patient counselling and optimizing therapy selection for those undergoing radical cystectomy.

Ten-fraction image-guided hypofractionated radiation therapy could be a feasible treatment option for portal vein tumor thrombosis in patients with HCC.

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.

The recommendation from the CHMP is based on results from the phase 2b HERIZON-BTC-01 trial of zanidatamab in advanced HER2+ biliary tract cancer.

Study data show a small number of individuals with a lung cancer diagnosis within 12 months of a negative baseline screening result.

The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

BMI, serum albumin, and G8 screening tool scores were all factors correlated with the likelihood of experiencing a grade 3 or higher AE.

Toxicity complications were assessed between single- and multiple-treatment modalities for patients with localized prostate cancer.

Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.

According to comparative single-cell transcriptome analyses, NOTCH1 deficiency facilitated a more immunologically active microenvironment in ESCC tumors.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Findings from clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.

Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.

Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.

SBRT demonstrated positive 3-year outcomes as a treatment in patients with early-stage HCC based on results from the phase 2 STRSPH trial.

Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.

“Food is powerful, and [patients] need fuel,” said Claudia Aguilar Clancy, RN, FNP-C, about ensuring patients receive the nutrition they require during cancer treatment.

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.